Evaluation of intramuscular olanzapine and ziprasidone in the medically ill

Seema M. Patel, PharmD, BCPP
Ericka L. Crouse, PharmD, BCPP, BCGP, FASHP, FASCP
James L. Levenson, MD

How to cite: Patel SM, Crouse EL, Levenson JL. Evaluation of intramuscular olanzapine and ziprasidone in the medically ill. Ment Health Clin [Internet]. 2021;11(1):6-11. DOI: 10.9740/mhc.2021.01.006.

Abstract

Introduction: Despite the paucity of studies evaluating short-acting parenteral second-generation antipsychotics in the medically ill, their use in this population has increased. The purpose of this study was to characterize the use of IM olanzapine and ziprasidone in the medically ill at an academic medical center.

Methods: This is a retrospective medical record review of all patients who received IM olanzapine or ziprasidone on nonpsychiatric inpatient units at a large academic medical center from August 1, 2015 to July 31, 2017. The primary endpoint characterized the indication for use. Secondary endpoints included safety, effectiveness, and prescribing patterns.

Results: After exclusion criteria, a total of 100 patients were included in this study, predominantly white males with a mean age of 56 years. Seventy-four percent of patients received IM ziprasidone and 26% received IM olanzapine. The most common indications for use were agitation of nonpsychotic origin (40%) and delirium (33%). Patients received IM olanzapine and ziprasidone when their use was contraindicated (26.9% vs 9.5%, respectively).

Discussion: Intramuscular second-generation antipsychotics are increasingly being used in the medically ill for delirium and agitation. Our study confirms these were the most common indications for IM second-generation antipsychotic use in this population. Additionally, their use appeared to be well-tolerated, and no patient developed Torsades de Pointes even when combined with other agents that putatively increase QTc. Given the retrospective, single-center, nonrandomized design of this study, the safety and effectiveness of these parenteral second-generation antipsychotics in common causes of acute agitation should continue to be further evaluated.

Keywords: agitation, intramuscular, olanzapine, ziprasidone, medically ill

Disclosures: The authors have no potential conflicts of interest or sources of funding to disclose with regards to the conducted research and prepared article.
acute agitation, however it is associated with extrapyramidal symptoms and a warning for corrected QT interval (QTc) prolongation with IV use. The previously published 2013 Society for Critical Care Medicine (SCCM) guidelines assert there is no supporting use of haloperidol for reducing delirium duration in adult intensive care unit patients and instead suggest that oral quetiapine may reduce the duration of delirium. The guidelines also recommend against using antipsychotics in patients at significant risk for torsades de pointes, including those with a baseline prolonged QTc or being administered concomitant QTc prolonging medications. Second-generation antipsychotics (SGAs) are less likely to cause extrapyramidal symptoms than first-generation antipsychotics, but SGAs may still prolong the QTc interval. Despite not having an approved indication outside of agitation related to schizophrenia or bipolar disorder, short-acting IM SGAs are increasingly being used in hospitalized medically ill patients. Available literature evaluating the use of IM SGAs in treating agitation in the medically ill is limited and includes an open-label study that examined the safety and efficacy of IM ziprasidone with geriatric patients experiencing psychosis and agitation (N=14), a retrospective study of the safety of IM ziprasidone in agitated hospitalized elderly patients (N=23), a retrospective case series of hospitalized patients who received IM olanzapine outside product doses and indications (N=10), and a retrospective study of IM olanzapine in the management of behavioral and psychological symptoms in hospitalized older adults (N=85), however only 34 patients actually received the IM olanzapine.

Two currently available short-acting IM SGAs are olanzapine and ziprasidone. Approval trials excluded medically ill patients and recent substance abuse. Key safety parameters that apply across patient populations include maximum daily dose, duration of use, avoiding IM ziprasidone in patients with a recent history of myocardial infarction or unstable heart disease, and avoiding parenteral benzodiazepine use within 1 hour of IM olanzapine. IM olanzapine should not be given within 1 hour of parenteral benzodiazepines because of the risk of over-sedation, cardiorespiratory depression, and hypotension. IM ziprasidone contains the cyclodextrin, a renally cleared excipient; therefore, should be used cautiously in renal impairment. Overall, many factors in the pivotal studies for IM ziprasidone and IM olanzapine make it difficult to extrapolate the results to patients with medical illnesses who may be receiving doses beyond maximum recommended daily dose and studied duration.

Because of the limited literature of IM olanzapine and ziprasidone in medically ill patients, the objective of this retrospective review is to characterize the use and safety of these SGAs in the medical-surgical inpatient population at an academic medical center.

Methods
This study was a retrospective medical record review of patients who received short-acting parenteral olanzapine or ziprasidone on nonpsychiatric units at a large academic medical center licensed for 790 beds, with an average daily census of 592, from August 1, 2015 to July 31, 2017. The Virginia Commonwealth University IRB approved this study. Potential patients were identified via a pharmacy medical record report of all charted doses of parenteral olanzapine or ziprasidone on nonpsychiatric units. The intention was to capture patients who received IM or IV SGAs. No patients received IV, therefore IM will be used throughout the rest of this publication. Patients were included if they were at least 18 years of age, admitted to a nonpsychiatric unit, and received parenteral short-acting olanzapine or ziprasidone. Exclusion criteria included patients who received IM olanzapine or ziprasidone only in the emergency department, upon transfer to a psychiatric unit, prisoners, and pregnant women. The primary endpoint was indication for use of IM olanzapine or ziprasidone. Baseline comorbidities of schizophrenia, bipolar disorder, schizoaffective disorder, substance use history, and dementia were collected to determine on-label and off-label prescribing.

Secondary endpoints included safety, effectiveness, and prescribing patterns of IM olanzapine and ziprasidone. Safety of IM olanzapine and ziprasidone was assessed by adverse effects (hypotension, sedation, and falls), change in QTc interval, mortality, and prescribing when contra-indicated. Adverse effect data was obtained from reviewing the medical record nursing notes, vital sign records, and Richmond Agitation-Sedation Scale (RASS) score. Rates of adverse effects with each agent were compared. Presence of concomitant medication(s) with known, possible, or conditional risk of prolonging the QTc, as defined by CredibleMeds were recorded. Effectiveness was assessed by the RASS, a validated scale ranging from +4 (combative) to −5 (unarousable). The RASS score was chosen as an objective measurement that is collected on the majority of intensive care unit and medically ill patients. Improvement was defined as a reduction in a positive score to 0 or −1 (alert and calm or drowsy) within 1 hour of the first IM olanzapine or ziprasidone dose. Lack of improvement was documented if RASS score was unchanged or increased within 1 hour of the first IM olanzapine or ziprasidone dose. Sedation was documented if RASS score was reduced to −2 or −3 (light sedation or moderate sedation) within 1 hour of each administration of IM olanzapine or ziprasidone. Prescribing patterns of IM olanzapine and ziprasidone in the medically ill were compared based on select baseline characteristics or comorbidities including age, prevalence of diabetes, hyperlipidemia, recent myocardial infarction, prolonged QTc, uncompensated heart failure, or renal impairment (creatinine clearance <50 mL/min). These
comorbidities were selected based on the exclusion criteria of pivotal trials, common adverse effects, as well as cautions and contraindications for each agent.

Statistical analyses were performed using JMP Pro Software version 13 (SAS Institute), with descriptive statistics for demographics and the primary endpoint. The χ² test was used to make comparisons between parenteral olanzapine and ziprasidone on secondary endpoints.

Results

Of the 138 total patients who received IM olanzapine or ziprasidone during the study period at a large academic medical center, 100 patients were included. Reasons for exclusion included patients on an inpatient psychiatric unit (n = 17), patients who received an antipsychotic only in the emergency department (n = 15), and patients who were less than 18 years of age (n = 6). Majority of patients were male (70%) and the mean age was 56 years (see Table 1). When evaluating patient characteristics, majority of patients (74%) received ziprasidone. The study institution uses both SGAs; however, at the time of data collection, IM ziprasidone was on formulary, whereas short-acting IM olanzapine was available for restricted use. Secondary to the risk of inadvertently combining IM olanzapine with parenteral benzodiazepines, short-acting IM olanzapine was restricted to inpatient adult psychiatry, child/adolescent psychiatry, and consult and liaison psychiatry; primarily for patients already on oral olanzapine or had a contraindication or adverse reaction to IM ziprasidone or IM haloperidol. A psychiatry consult was obtained in 38 patients, often after the IM SGA was administered. The most common indication for use of IM olanzapine or ziprasidone was agitation of non-psychotic origin (40%), followed by delirium (33%; Table 2).

A total of 6 (23.08%) patients who received IM olanzapine were given the medication beyond the studied duration of 24 hours. A total of 10 (13.51%) patients who received IM ziprasidone were given the medication beyond the studied duration of 3 days. The most common adverse effect for

**TABLE 1: Summary of baseline characteristics and intramuscular olanzapine or ziprasidone administration**

| Patient Characteristics | N = 100 |
|-------------------------|---------|
| Age (y), mean ± SD      | 56 ± 17.5 |
| Male, %                 | 70 |
| Ethnicity, %            |         |
| White                   | 62 |
| African-American        | 36 |
| Hispanic                | 2 |
| Baseline QTc on admission (msec), median | 462 (n = 86) |
| Comorbid severe mental illness,a % | 17 |
| History of substance abuse, % | 35 |
| History of dementia, %  | 13 |
| NPO status, %           | 34 |
| Psychiatry consult, %   | 38 |
| Received IM ziprasidone, % | 74 |
| Received IM olanzapine, % | 26 |
| Received a parenteral FGA prior to an IM SGA, % | 40 |
| Received the IM SGA in an ICU, % | 64 |
| Received IM SGA beyond studied duration, n (% of treatment arm) |         |
| Olanzapine              | 6 (23.08) |
| Ziprasidone             | 10 (33.3) |
| Received IM SGA when use was contraindicated, n (% of treatment arm) |         |
| Olanzapine              | 7 (26.9) |
| Ziprasidone             | 7 (9.5) |

FGA = first-generation antipsychotic; msec = milliseconds; NPO = unable to take medications by mouth; QTc = corrected QT interval; SGA = second-generation antipsychotic.

*Severe mental illness was defined as schizophrenia (n = 8), schizoaffective disorder (n = 7), or bipolar disorder (n = 2).

**TABLE 2: Intramuscular second-generation antipsychotic indication for use and characteristics**

| Indication                        | N = 100 |
|-----------------------------------|---------|
| On-label, %                       | 5 |
| Off-label, %                      | 95 |
| Psychiatric disorder,a %          | 8 |
| Agitation of non-psychotic origin,b % | 40 |
| Delirium, %                       | 33 |
| Dementia-related agitation, %     | 4 |
| Other,c %                         | 11 |
| Unknown                            | 4 |

Characteristics

- Median total dosage in 24 h, mg (range)
  - Olanzapine: 6.3 (2.5-20)
  - Ziprasidone: 20 (20-40)
- Duration of use, d (median)
  - Olanzapine: 1-4 (1)
  - Ziprasidone: 1-17 (1)
- Median total cumulative dose received, mg (range)
  - Olanzapine: 8.8 (2.5-60)
  - Ziprasidone: 20 (10-210)

*aSchizophrenia (n = 5), schizoaffective disorder (n = 2), bipolar disorder (n = 1).

*bTraumatic brain injury (n = 13); alcohol withdrawal syndrome (n = 9); substance abuse (n = 4); post-ischemic stroke (n = 3); hepatic encephalopathy (n = 3); seizures (n = 2); anti-N-methyl-d-aspartate encephalitis (n = 2); severe intellectual disability (n = 2); cerebral amyloid angiopathy related to inflammation (n = 1); hyponatremia (n = 1); dexamethasone (n = 1); levetiracetam (n = 1).

*cCentral line procedure (n = 3); mixed etiology (n = 4); infection (n = 2); used for sedation (n = 1); altered mental status due to hypercapnia (n = 1).

8 Ment Health Clin [Internet]. 2021;11(1):6-11. DOI: 10.9740/mhc.2021.01.006
patients who received IM olanzapine or IM ziprasidone was sedation. There was no significant difference in rates of sedation between IM olanzapine or IM ziprasidone (34.62% vs 24.32%; \( P = .32 \)), respectively. Significantly more patients who received IM olanzapine had hypotension compared to those who received IM ziprasidone (23.08% vs 6.76%; \( P = .022 \)). Falls occurred at similar rates in both IM olanzapine (7.7%) and IM ziprasidone (8.1%). No patients died.

Of the patients who had a baseline QTc (Bazett’s correction formula) on admission (\( n = 86 \)), the mean QTc was 462 milliseconds (msec). Patients who received IM olanzapine had a higher baseline QTc than the ziprasidone group (473.2 msec vs 464.9 msec, respectively). Only 57 patients had a follow-up electrocardiogram after their last dose, 34.6% (\( n = 19 \)) of olanzapine versus 51.4% (\( n = 38 \)) of ziprasidone patients. Approximately 42.1% (\( n = 8 \)) of olanzapine and 34.2% (\( n = 13 \)) of ziprasidone patients experienced an increase in their QTc interval. The median (interquartile range) change in QTc from baseline for IM olanzapine was 36.5 (5.3-52.3) msec and 16 (10-42.5) msec in patients who received IM ziprasidone. Additionally, the majority of patients (71%) had received concomitant medication(s) with known, possible, or conditional risk of prolonging the QTc, as defined by CredibleMeds (this was equally true for both medications). Oral antipsychotics were the most commonly coprescribed QTc prolonging agents that were received: haloperidol (\( n = 44 \)), quetiapine (\( n = 37 \)), olanzapine (\( n = 6 \)), risperidone (\( n = 3 \)), lurasidone (\( n = 1 \)), ziprasidone (\( n = 1 \)), and trifluoperazine (\( n = 1 \)). Other QTc prolonging psychotropic agents coprescribed and received were citalopram (\( n = 1 \)), lithium (\( n = 1 \)), nortriptyline (\( n = 1 \)), and sertraline (\( n = 1 \)).

Thirty-three (33%) patients received 2 or more additional QTc prolonging agents, with 1 patient receiving 4 QTc prolonging agents in addition to ziprasidone. Given the limitations of using CredibleMeds and the inconclusive effects of some of these medications on the QTc (eg, sertraline, lithium), no conclusions or associations can be made between the concomitant medications used and their effect on QTc interval. Of those who had a RASS score documented after the first dose, improvement was seen in 11 (42.31%) patients who received IM olanzapine and 30 (40.54%) patients who received IM ziprasidone. However, this was not documented in over half of the patients after receiving the first dose of IM olanzapine or IM ziprasidone (57.79% vs 55.41%). Lack of improvement was documented in 0% and 4.05% after IM olanzapine and IM ziprasidone, respectively.

There were no statistically significant differences in prescribing patterns based on baseline medical history between patients who received IM olanzapine vs those who received IM ziprasidone. Seven patients received IM ziprasidone when it was contraindicated, 2 who had a recent myocardial infarction and 5 who had uncompensated heart failure (Table 3). Seven patients who received IM olanzapine were given a parenteral benzodiazepine within 1 hour of administration.

## Table 3: Comparison of prescribing patterns of IM olanzapine versus IM ziprasidone

| Baseline Medical History, n (%) | Olanzapine (\( n = 26 \)) | Ziprasidone (\( n = 74 \)) | \( P \) Valuea |
|-------------------------------|---------------------------|---------------------------|----------------|
| Diabetes                      | 6 (23.08)                 | 20 (27.03)                | .69            |
| Age ≥65 y                     | 7 (26.92)                 | 19 (25.68)                | .90            |
| Hyperlipidemia                | 1 (3.85)                  | 6 (8.11)                  | .46            |
| Recent myocardial infarction   | 3 (11.54)                 | 2 (2.70)                  | .075           |
| QTc interval ≥450 msec\(^b\)  | 15 (60)                   | 36 (59.2)                 | .93            |
| QTc interval ≥500 msec\(^b\)  | 6 (24)                    | 9 (14.8)                  | .30            |
| Uncompensated heart failure    | 1 (3.85)                  | 5 (6.76)                  | .59            |
| Renal impairment (CrCl < 50 mL/min) | 9 (34.61)                 | 13 (17.57)                | .071           |

CrCl = creatinine clearance; msec = milliseconds; QTc = corrected QT interval.

aPercent calculated based on electrocardiograms obtained olanzapine \( n = 25 \), ziprasidone \( n = 61 \).

**Discussion**

In this retrospective medical record review of 100 medically ill patients who received IM olanzapine or ziprasidone at an academic medical center, the most common indication for use was agitation of nonpsychotic origin (40%), followed by delirium (33%). This supports the clinical experience that these agents are increasingly being used for these indications. Two published cases of sudden and unexpected deaths in patients with schizophrenia who received high doses of IM haloperidol and IM ziprasidone led to practice guidelines to limit the use of high doses of IM antipsychotics. In this study, no patient received more than the maximum recommended total daily IM dose of either antipsychotic. One patient received...
50 mg of ziprasidone in IM equivalents, with IM and oral route combined (IM = 20 mg + oral = 120 mg [30 mg in IM equivalents]).

Despite a prolonged baseline QTc or concurrent QTc prolonging medications many patients still received IM ziprasidone; however, similar to Greco et al, none of these cases resulted in Torsades de Pointes. The high rates of concomitant quetiapine reflect its recommendation for agitation in the 2013 SCCM guidelines, as well as the high rates of haloperidol reflect its historical use for agitation in this population. Since completion of our study, SCCM published an updated 2018 guideline which again discourages routine use of haloperidol or antipsychotics to treat delirium. However, they suggest patients who experience significant distress or agitation and may be at harm to themselves or others may benefit from short-term use of an SGA or haloperidol. Clinical pharmacists in the intensive care unit setting can help reduce the number of patients who remain on these agents after symptom resolution or discharge. The greater change in QTc from baseline in patients who received IM olanzapine may be explained by the higher baseline QTc in this group and possibly by prescribers selectively choosing IM olanzapine over ziprasidone for these patients judged to be at higher risk for QTc prolongation. Patients with baseline prolonged QTc may also have had other risk factors for QTc prolongation, which were not accounted for. Therefore it is difficult to draw conclusions regarding change in QTc in this population. Furthermore, the medically ill population may be on multiple other antihypertensives or experience dehydration, which also was not accounted for. Our study found rates of hypotension significantly higher with IM olanzapine (23.08%) than IM ziprasidone (6.76%); similarly the previous studies regarding IM olanzapine also had high rates of orthostatic hypotension (12.5% and 14.7%). Dong et al reported falls in 4 of 34 (11.8%) elderly patients within 24 hours of receipt of IM olanzapine, a rate higher than the approximate 8% described in our study. This may also be reflective of the younger age of our population. This is the largest study to date retrospectively evaluating the use of IM SGAs in the medically ill on nonpsychiatric units at an academic medical center. Most previous data have primarily been in elderly patients, primarily with dementia, and this study included younger medically ill adults. The previous IM ziprasidone studies focused on older adults on psychiatric or neuropsychiatric units, whereas in the IM olanzapine studies 50% or greater of the population was inpatient psychiatry. Of the previous literature, Lamoure and Rudnick looked at the off-label uses of IM olanzapine in 8 patients (average age 43.9 years [range 18-77]) across 10 admissions which included patients on a surgery floor (n = 4) and internal medicine (n = 1). Fifty percent of patient encounters had concurrent alcohol or substance withdrawal or intoxication, and 2 had a TBI. Our study adds to the limited safety data of using these agents in the medically ill with concurrent substance abuse or intoxication.

However, there are several limitations to this study including a retrospective, single-center study design, small sample size, a relatively high percentage of patients who received a parenteral first-generation antipsychotic prior to receiving the IM SGA, and incomplete documentation in the electronic medical record. Additionally, the low number of patients who received IM olanzapine may be accounted for by the nonformulary status of this medication at this institution. There may have been other confounding variables that could have caused the adverse effects noted, so it is difficult to correlate these adverse effects directly with the IM SGA administered. Evaluating for improvement in RASS score was only performed after the first dose. Therefore, it is possible that improvement after further doses could have occurred. Furthermore, the exact change from baseline in RASS score to evaluate for effectiveness was not documented. A total of 7 patients received parenteral benzodiazepines within 1 hour of IM olanzapine administration. None of these patients experienced any adverse effects. Marder et al advised caution when using IM olanzapine and parenteral benzodiazepines concomitantly after observing 29 fatal cases of IM olanzapine, of which 15 (51.7%) reported concomitant oral, IV, or IM benzodiazepine use. The lack of adverse effects seen with this combination in our study may be due to limitations in documentation and the small number of patients receiving this combination.

Since the completion of this study, our institution also completed a medication-use evaluation on short-acting IM olanzapine (in psychiatric patients) and it was ultimately added to formulary, without restrictions. A pharmacy-specific alert warns the verifying pharmacist to review the medication profile for parenteral benzodiazepines and suggest discontinuation. Additionally, the institutional product instructions for use state to not administer within 1 hour of a parenteral benzodiazepine.

**Conclusion**

This study characterizes the indications and clinical safety data of IM olanzapine and ziprasidone in the medically ill. IM SGAs are currently being used more often in the medically ill for delirium and agitation. Our findings confirm these were the most common indications for IM SGA use. This study also adds to the limited safety data of IM SGAs for these off-label indications. Our data supports the clinical experience that Torsades de Pointes did not occur even when combining IM SGAs with other agents that putatively increase QTc. Additional data is still
needed to continue to support and evaluate the safety and effectiveness of parenteral SGAs in common causes of acute agitation in medically ill as well as compare their use to haloperidol in this population.

Acknowledgments

We thank Katie Adams, PharmD, BCPP, Sandra Mullen PharmD, BCPP, and Teresa Potter, PharmD, MPH, BCPS.

References

1. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and Torsades de Pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16.
2. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(2):262-306. DOI: 10.1097/CCM.0b013e3182783b72. PubMed PMID: 23269131.
3. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):442-8. DOI: 10.1001/archpsyc.59.5.442. PubMed PMID: 11982448.
4. Pfizer Inc. Geodon (ziprasidone mesylate) injection [Internet]. New York: National Library of Medicine (US); c2001 [updated 2015 July; cited 2019 Dec 20]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8519997d-8e02-4810-88e1-bff4d39873ee&type=display
5. Lilly USA, LLC. Zyprexa (olanzapine) injection [Internet]. Indianapolis (IN): National Library of Medicine (US); c2016 [updated 2015 July; cited 2019 Dec 20]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=85688d8f-f2de-408a-8ae2-0976c266c961&type=display
6. Rais AR, Williams K, Rais T, Sing T, Tamburrino M. Use of intramuscular ziprasidone for the control of acute psychosis or agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2012;40(11):e1036-7. PubMed PMID: 23047279.
7. Greco KE, Tune LE, Brown FW, Van Horn WA. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry. 2005;66(7):926-5. DOI: 10.4088/jcp.v66n0717. PubMed PMID: 16033910.
8. Duong S, Yeung K-T, Chang F. Intramuscular olanzapine in the management of behavioral and psychological symptoms in hospitalized older adults: a retrospective descriptive study. J Aging Res. 2015;2015(21):1-6. DOI: 10.1155/2015/570420. PubMed PMID: 26090227; PubMed Central PMCID: PMC4458274.
9. Lamoure JW, Rudnick A. A retrospective (post-marketing) case series of patients receiving intramuscular (IM) olanzapine outside of product doses and indications (off-label): assessing safety and tolerability. Clin Med Insights: Psychiatry. 2011;5:CMpsy.S6550. DOI: 10.4137/CMPsy.S6550.
10. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389-97. DOI: 10.1097/00004714-200108000-00006. PubMed PMID: 11476123.
11. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48(11):716-21. DOI: 10.1177/070674370304801102. PubMed PMID: 14733451.
12. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology. 2001;155(2):128-34. DOI: 10.1007/s002130000658. PubMed PMID: 11401000.
13. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62(12):18-28. DOI: 10.1097/00004714-200112000-00001. PubMed PMID: 11982448.
14. Pfizer Inc. Geodon (ziprasidone mesylate) injection [Internet]. New York: National Library of Medicine (US); c2004 [updated 2005 July; cited 2019 Dec 20]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8519997d-8e02-4810-88e1-bff4d39873ee&type=display
15. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, et al. Intramuscular olanzapine and intramuscular haloperidol in acute agitation, and delirium in an inpatient geriatric population. Psychiatry (Edgmont). 2010;7(1):17-24. PubMed PMID: 20386633.
16. Sessler CN, Grap MJ, Brophy GM. Multidisciplinary management of sedation and analgesia in critical care. Semin Respir Crit Care Med. 2013;41(1):263-306. DOI: 10.1097/CCM.0b013e3182783b72. PubMed PMID: 23269131.
17. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66(12):1614-5. DOI: 10.4088/jcp.08m0441gr. PubMed PMID: 20156413.
18. Laher RU, Frank M. Use of intramuscular olanzapine in elderly patients with agitation: a retrospective study. J Clin Psychiatry. 2010;71(4):433-41. DOI: 10.4088/jcp.08m0441gr. PubMed PMID: 20156413.
19. Hale SW, Greer T, Darvish Y, et al. An unexpected death of a patient with schizophrenia associated with intramuscular olanzapine injection and practice guidelines to limit the use of high doses of intramuscular antipsychotics. Case Rep Psychiatry. 2016;2016(17):1-14. DOI: 10.1155/2016/9406813. PubMed PMID: 27597959; PubMed Central PMCID: PMC5002457.
20. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-73. DOI: 10.1097/CCM.0000000000003299. PubMed PMID: 30213379.